Lung Cancer News

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

CHICAGO — ChatGPT can be used to develop next-generation sequencing reports that outline treatment strategies for patients who have non-small cell lung cancer with driver oncogenes, according to results presented at ASCO Annual Meeting.

CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting.

CHICAGO — The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for adults with advanced malignant pleural mesothelioma, according to results of the randomized phase 3 IND.227/KEYNOTE-483 trial.

CHICAGO — A study that assessed the feasibility of lung cancer screening for certain nonsmokers yielded a higher invasive adenocarcinoma detection rate than the National Lung Screening Trial, which assessed screening for smokers who met key risk criteria.

CHICAGO — Adding talazoparib to atezolizumab as maintenance treatment after front-line chemoimmunotherapy significantly lengthened PFS among adults with SLFN11-positive extensive-stage small cell lung cancer, according to a phase 2 study.

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ADAURA trial presented at ASCO Annual Meeting.

CHICAGO — The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes for patients with early-stage resectable non-small cell lung cancer, according to findings presented at ASCO Annual Meeting.

CHICAGO — Platinum-doublet chemotherapy did not extend survival for patients with advanced nonsquamous non-small cell lung cancer who responded to EGFR tyrosine kinase inhibitor therapy, according to randomized phase 3 study results.

Patients with early-stage non-small cell lung cancer who underwent surgical resection had higher rates of long-term survival than those who received stereotactic body radiation therapy, according to study results.